Sainz Maria 4

4 · PULSE BIOSCIENCES, INC. · Filed Jun 15, 2026

AI-generated summary of this filing

Updated Jun 16, 2026

Pulse Biosciences (PLSE) Director Maria Sainz Receives Equity Awards

What Happened

Maria Sainz, a director of Pulse Biosciences (PLSE), was granted two derivative equity awards on June 11, 2026: 30,000 shares and 3,793 shares. The reported acquisition price is $0.00, indicating these were awards (not open-market purchases) and no cash was paid at grant. The filing does not state an immediate cash value or sale of shares.

Key Details

Transaction date: 2026-06-11; Form 4 filed 2026-06-15 (timely filing).
Award amounts: 30,000 shares (derivative) and 3,793 shares (derivative); reported price $0.00.
Shares owned after transaction: not specified in the filing.
Vesting: 30,000-share award vests in equal monthly installments over one year, first vesting on July 11, 2026 (Footnote F1). The 3,793-share award vests in equal quarterly installments over one year, first vesting on September 5, 2026 (Footnote F2).
No 10b5-1 plan, tax-withholding sale, or exercise-for-cash indicated in the filing.

Context

These are compensation awards (derivative grants) that vest over time contingent on continued service; they are common director compensation and do not represent an open-market buy or sale. Because vesting is staggered, the awards do not result in immediate shares available for sale unless further actions (e.g., settlement or exercise) occur later.

Form 4

Period: 2026-06-11

Director

Transactions

Award
Stock Option (right to buy)
[F1]
2026-06-11+30,000→ 30,000 total
Exercise: $26.89Exp: 2036-06-11→ Common Stock (30,000 underlying)
Award
Stock Option (right to buy)
[F2]
2026-06-11+3,793→ 3,793 total
Exercise: $26.89Exp: 2036-06-11→ Common Stock (3,793 underlying)

Footnotes (2)

[F1]The shares subject to the option will vest in equal monthly installments over a one-year period, subject to the Reporting Person's continued service through each vesting date, with the first such installment occurring on July 11, 2026.
[F2]The shares subject to the option will vest in equal quarterly installments over a one-year period, subject to the Reporting Person's continued service through each vesting date, with the first such installment occurring on September 5, 2026.

Signature

/s/ Kenneth B. Stratton|2026-06-15

1 file